ResearchAGIO

AGIO: FY25 Deep Dive

Ddrillr ResearchOriginal research

Published Sep 3, 20261 min read

Summary

Agios Pharmaceuticals FY25 at $54M. NI $-413M; EPS $-7.12.

FY25 revenue $54M; OI $-472M; NI $-413M; EPS $-7.12.

Agios Pharmaceuticals FY25 (Dec 31, 2025) at $54M revenue. OpInc $-472M; NI $-413M; EPS $-7.12. Biotech — Hematology.